The majority of ER+ breast cancer cells, however, do have intact Rb and it is therefore urgent to identify other clinically useful predictive biomarkers before treatment with CDK4/6 inhibitors (Carey and Perou, 2015). The gene discussed is CDK4; the disease is breast cancer.